Approximately 390 million dengue virus infections occur every year, out of which 96 million of the cases manifest clinically. It is estimated that 3.9 billion individuals are at risk of getting a dengue virus infection, with Asia reported to represent nearly 70% of the global disease burden. The dengue pipeline analysis explores the latest medications and vaccinations, currently in development. The surge in dengue cases, along with rapid advancements in vaccine development and regulatory support, is likely to expedite the development of several promising dengue drugs in the coming years.
Major companies involved in the dengue pipeline drugs include Novartis Pharmaceuticals and Takeda, among others.
Leading drugs currently under the pipeline include Dengue Tetravalent Vaccine (TDV) and EYU688, among others.
The rising incidence of dengue and advances in biotechnology and drug delivery systems are expected to positively influence the dengue pipeline landscape.
The Dengue Pipeline Analysis Report by Expert Market Research gives comprehensive insights into dengue therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Dengue. The dengue report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The dengue pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with dengue treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to dengue.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Dengue, a mosquito-borne disease, is caused by dengue virus and is spread by the bite of an infected Aedes mosquito. It is prevalent in tropical and subtropical areas and leads to flu-like symptoms such as high fever, skin rash and itching, headache, vomiting, and muscle and joint pain. Dengue fever can develop into severe dengue in a small number of cases.
There is no specific treatment for dengue, but there are some common dengue therapeutics that can aid in managing symptoms. Pain relievers such as Acetaminophen (Tylenol) are widely used for fever and muscle pain. Pharmaceutical companies are actively developing novel drug candidates such as antiviral agents, vaccines, and monoclonal antibodies. Additionally, streamlined approval processes and incentives for new dengue drugs, along with dengue treatment guidelines, are poised to improve patient outcomes and support pipeline expansion in the coming years. In May 2024, the World Health Organization (WHO) prequalified TAK-003, a dengue vaccine developed by Takeda. TAK-003 is a live-attenuated vaccine containing weakened versions of all four dengue virus serotypes. It is recommended for children aged 6–16 years in high-burden areas. WHO prequalification enables procurement by agencies like UNICEF and PAHO, expanding global vaccine access.
According to the World Health Organisation (WHO), around half of the global population is at risk of getting a dengue infection. It is estimated that 100 to 400 million dengue infections occur annually, with individuals having second-time infections at a greater risk of developing severe dengue.
The incidence of dengue is reported to be dramatically increasing worldwide in recent decades. In 2023, the highest number of dengue cases was recorded, with more than 6.5 million people affected and over 7300 dengue-related deaths.
This section of the report covers the analysis of dengue drug candidates based on several segmentations including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The pipeline assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
The dengue report assessment covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials, with a substantial number of dengue emerging drugs undergoing clinical development. Phase II holds the largest share at 50%, demonstrating strong advancements in Dengue drug development. Phase III follows with 41%, highlighting promising late-stage trials. Phase I contributes 5%, while Early Phase I accounts for 4%, indicating continuous innovation. These developments enhance treatment options, drive market growth, and improve global efforts to combat Dengue effectively.
The drug molecule categories covered under the dengue pipeline analysis include oligonucleotide, peptide, and small molecule. The dengue report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for the disease. The pipeline includes antiviral and vaccine-based approaches to combat the disease. As per a press release by Panacea Biotec, the company’s tetravalent dengue vaccine, DengiAll has entered Phase III trials in India. Additionally, antiviral candidates targeting dengue virus replication, such as EDP-938, are under investigation. These developments aim to address the growing burden of dengue globally.
The EMR report for the dengue pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed dengue therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in dengue clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for vitiligo. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of dengue drug candidates.
Sponsored by Takeda, the objective of this randomized, double-blinded, multicenter clinical trial is to investigate the immunogenicity and safety of Dengue Tetravalent Vaccine (TDV) for protection against dengue. The study is under Phase III clinical development and has an estimated 800 participants.
Novartis Pharmaceuticals is conducting a Phase II clinical trial aimed at examining the efficacy, pharmacokinetics, and safety of dengue drug candidate EYU688, in comparison to placebo. The interventional study has enrolled about 5 subjects and is expected to be completed by February 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Dengue Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for dengue. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within dengue pipeline insights.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share